Vincent Haddad

4.4k total citations · 2 hit papers
36 papers, 2.9k citations indexed

About

Vincent Haddad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Vincent Haddad has authored 36 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Vincent Haddad's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Vincent Haddad is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer Treatment and Pharmacology (7 papers). Vincent Haddad collaborates with scholars based in United Kingdom, France and United States. Vincent Haddad's co-authors include Jean‐Charles Soria, Fabrice André, Ariane Dunant, Jean‐Pierre Pignon, Robert Pirker, Helmut Popper, Élisabeth Brambilla, Thierry Le Chevalier, Martin Filipits and Rolf A. Stahel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Vincent Haddad

34 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

2006 1.3k citations Ken A. Olaussen, Ariane Dunant et al. New England Journal of Medicine profile →
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

2018 516 citations Nicola Gökbuget, Hervé Dombret et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincent Haddad United Kingdom	16	1.5k	1.3k	907	485	414	36	2.9k
Ashish M. Ingle United States	24	788 0.5×	673 0.5×	1.2k 1.3×	348 0.7×	354 0.9×	36	2.5k
Syma Iqbal United States	29	2.0k 1.3×	993 0.7×	901 1.0×	358 0.7×	539 1.3×	129	3.1k
Mrinal M. Gounder United States	31	1.9k 1.2×	1.8k 1.4×	1.1k 1.2×	318 0.7×	648 1.6×	164	3.7k
Edward M. Newman United States	26	1.2k 0.8×	431 0.3×	1.1k 1.2×	199 0.4×	391 0.9×	88	2.4k
Clet Niyikiza United States	15	1.4k 0.9×	3.0k 2.3×	585 0.6×	176 0.4×	125 0.3×	29	3.8k
Nikolas von Bubnoff Germany	31	1.1k 0.7×	444 0.3×	1.1k 1.2×	537 1.1×	481 1.2×	138	4.1k
Drew Rasco United States	33	2.4k 1.6×	980 0.7×	1.7k 1.9×	516 1.1×	422 1.0×	192	4.1k
Lillian Werner United States	29	823 0.5×	891 0.7×	711 0.8×	499 1.0×	402 1.0×	126	2.4k
Wael A. Harb United States	23	1.4k 0.9×	759 0.6×	923 1.0×	423 0.9×	247 0.6×	118	2.5k
Shuchi S. Pandya United States	19	980 0.6×	900 0.7×	895 1.0×	365 0.8×	156 0.4×	69	2.1k

Countries citing papers authored by Vincent Haddad

Since Specialization

Citations

This map shows the geographic impact of Vincent Haddad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent Haddad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent Haddad more than expected).

Fields of papers citing papers by Vincent Haddad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent Haddad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent Haddad. The network helps show where Vincent Haddad may publish in the future.

Co-authorship network of co-authors of Vincent Haddad

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent Haddad. A scholar is included among the top collaborators of Vincent Haddad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent Haddad. Vincent Haddad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zariffa, Névine, Katherine K. Nishimura, Yu Deng, et al.. (2025). Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy. Journal for ImmunoTherapy of Cancer. 13(9). e012454–e012454.

Manitz, Juliane, Hannes Buchner, Evgeny Degtyarev, et al.. (2021). Estimands for overall survival in clinical trials with treatment switching in oncology. Pharmaceutical Statistics. 21(1). 150–162. 16 indexed citations

Gökbuget, Nicola, Hervé Dombret, Massimiliano Bonifacio, et al.. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131(14). 1522–1531. 516 indexed citations breakdown →

Oza, Amit M., David Cibula, Ana Oaknin, et al.. (2018). Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy. Annals of Oncology. 29. viii340–viii340. 1 indexed citations

Frigault, Melanie M., Sabina Signoretti, Aleksandra Markovets, et al.. (2018). Abstract 4541: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor. Cancer Research. 78(13_Supplement). 4541–4541. 2 indexed citations

Choueiri, Toni K., Regina I. Jakacki, Dana Ghiorghiu, et al.. (2017). Savolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial. Annals of Oncology. 28. v328–v328. 6 indexed citations

Mok, Tony, Sang‐We Kim, Yi‐Long Wu, et al.. (2017). Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. Journal of Clinical Oncology. 35(36). 4027–4034. 129 indexed citations

Wu, Yi‐Long, Nagahiro Saijo, Sumitra Thongprasert, et al.. (2016). Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 104. 119–125. 40 indexed citations

Normanno, Nicola, Heather A. Brown, Vincent Haddad, et al.. (2016). 580_PR: Clinical and demographic features that influence EGFR mutation detection in plasma from patients (pts) with aNSCLC: The ASSESS experience. Journal of Thoracic Oncology. 11(4). S151–S151. 4 indexed citations

10.

Han, Baohui, M. Ratcliffe, Vincent Haddad, et al.. (2016). 59PD Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis. Journal of Thoracic Oncology. 11(4). S79–S80. 1 indexed citations

11.

Mok, Tony, Nagahiro Saijo, Sumitra Thongprasert, et al.. (2015). 426PD Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC. Annals of Oncology. 26. ix125–ix125. 1 indexed citations

12.

Goekbuget, Nicola, Hervé Dombret, Massimiliano Bonifacio, et al.. (2014). BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL). Blood. 124(21). 379–379. 43 indexed citations

13.

Paz‐Ares, Luis, Beatrix Bálint, Richard H. De Boer, et al.. (2013). A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(3). 329–337. 58 indexed citations

14.

Besse, Benjamin, C. Massard, Vincent Haddad, et al.. (2010). ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Annals of Oncology. 22(3). 575–581. 14 indexed citations

15.

Massard, Christophe, Vincent Haddad, Jean‐Pierre Pignon, et al.. (2009). Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice. Journal of Thoracic Oncology. 4(12). 1504–1510. 13 indexed citations

16.

Filipits, Martin, Vincent Haddad, Katharina Schmid, et al.. (2007). Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non–Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clinical Cancer Research. 13(13). 3892–3898. 66 indexed citations

17.

Brambilla, Élisabeth, Jean‐Charles Soria, Vincent Haddad, et al.. (2007). PD2-3-4: Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial. Journal of Thoracic Oncology. 2(8). S444–S445. 5 indexed citations

18.

Bonvalot, Sylvie, Hany Eldweny, Vincent Haddad, et al.. (2007). Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. European Journal of Surgical Oncology. 34(4). 462–468. 211 indexed citations

19.

Filipits, Martin, Robert Pirker, Ariane Dunant, et al.. (2007). Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. Journal of Clinical Oncology. 25(19). 2735–2740. 94 indexed citations

20.

Olaussen, Ken A., Ariane Dunant, Pierre Fouret, et al.. (2006). DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. New England Journal of Medicine. 355(10). 983–991. 1320 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact